Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)



Status:Recruiting
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - Any
Updated:6/2/2018
Start Date:March 19, 2016
End Date:March 2022
Contact:Cindy Daniel, CCRP
Email:cindy.daniel@utsouthwestern.edu
Phone:214-645-9165

Use our guide to learn which trials are right for you!

Multi-center, Randomized, Double-blinded Assessment of Tecfidera® in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)

The purpose of this investigation is to systematically study the efficacy of Tecfidera in
those individuals who possess incidental white matter anomalies within the brain following a
MRI study that is performed for a reason other than for the evaluation of MS (multiple
sclerosis).

This is a multi-center, randomized, double-blinded study in which approximately 210 RIS
(radiologically isolated syndrome) subjects will be treated with either Tecfidera or placebo
for 2 years (1:1 randomization). Study participants, along with the treating and examining
physicians, will be blinded to treatment assignment. Central Clinical and Imaging Units will
screen all potential study subjects for inclusion/exclusion criteria. We expect to enroll all
RIS subjects within the U.S.

Following informed consent and verification of entry criteria by the core units, study
participants will be randomized 1:1 to either Tecfidera (120mg by mouth twice daily for 7
days with dose escalation to 240mg by mouth twice daily) or placebo. Clinical follow-up by
the treating physician will occur at weeks 0, 48, 96, 144 and/or End of Study and during or
immediately following clinical exacerbations. During clinical visits, comprehensive medical
history data will be obtained by the treating physician. All reported acute or progressive
clinical events will be adjudicated by the Central Clinical Unit. Clinical visits due to
suspected exacerbations associated with CNS (central nervous system) demyelination, and
associated diagnostic studies and treatments, will be covered under the medical standard of
care by third party payers. A recommendation to re-evaluate the patient within 3 months
following the clinical event to assess for extent of recovery will be made. In addition to
the face-to-face visits described above, study participants will be contacted over the
telephone at weeks 4, 8, 36, 60, 84, 108, and 132 to assess for medical or treatment
difficulties and for study medication compliance. Standardized MRI studies of the brain will
be performed at weeks 0, 96, 144 or End of Study. Clinical imaging studies of the brain
and/or spinal cord performed during or immediately following the onset of a clinical
exacerbation will be performed at the discretion of the site PI with scan costs covered under
the medical standard of care. An end of study clinical MRI of the cervical spinal cord with
and without contrast will be recommended to study participants at week 96 as medical standard
of care.

Inclusion criteria

1. Males and females meeting 2009 RIS criteria

2. Identified RIS cases with the initial MRI demonstrating anomalies suggestive of
demyelinating disease dated > 2009

3. Incidental anomalies identified on MRI of the brain or spinal cord with the primary
reason for the acquired MRI resulting from an evaluation of a process other than MS

4. CNS white matter anomalies meeting the following MRI criteria:

- Ovoid, well-circumscribed, and homogeneous foci with or without involvement of
the corpus callosum

- T2-hyperintensities measuring > 3mm2 and fulfilling 3 of 4 Barkhof-Tintoré
criteria for dissemination in space

- CNS anomalies not consistent with a vascular pattern

- Qualitative determination that CNS anomalies have a characteristic appearance of
demyelinating lesions

5. MRI anomalies do not account for clinically apparent neurological impairments in
patients

Exclusion criteria

1. Women who are pregnant or nursing

2. Incomplete medical history or radiological data

3. History of remitting clinical symptoms consistent with multiple sclerosis lasting > 24
hours prior to CNS imaging revealing anomalies suggestive of MS

4. History of paroxysmal symptoms associated with MS (i.e. Lhermitte's or Uhthoff's
phenomena)

5. CNS MRI anomalies are better accounted for by another disease process

6. The subject is unwilling or unable to comply with the requirements of the study
protocol

7. Exposure to a disease modifying therapy for MS/RIS within the past 3 months

8. Exposure to high-dose glucocorticosteroid treatment within the past 30 days

9. Participation in other clinical trials involving treatment with a disease-modifying
agent
We found this trial at
16
sites
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
Principal Investigator: Timothy Vollmer, MD
Phone: 303-724-6386
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
4202 E Fowler Ave
Tampa, Florida 33620
(813) 974-2011
Principal Investigator: Derrick Robertson, MD
Phone: 813-974-6378
University of South Florida The University of South Florida is a high-impact, global research university...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Baltimore, Maryland 21287
Principal Investigator: Ellen Mowry, MD
Phone: 410-614-9201
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Burlington, Vermont 05401
Principal Investigator: Andrew Solomon, MD
Phone: 802-847-0983
?
mi
from
Burlington, VT
Click here to add this to my saved trials
Columbus, Ohio 43214
Principal Investigator: Aaron Boster, MD
Phone: 614-566-1268
?
mi
from
Columbus, OH
Click here to add this to my saved trials
2201 Inwood Rd
Dallas, Texas 75235
(214) 645-8300
Principal Investigator: Darin T Okuda, MD
Phone: 214-645-9165
U.T. Southwestern Medical Center The story of UT Southwestern Medical Center is one of commitment...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 75246
Principal Investigator: Annette Okai, MD
Phone: 214-818-2539
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Las Vegas, Nevada 89106
Principal Investigator: Le Hua, MD
Phone: 702-701-7669
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Los Angeles, California 90089
Principal Investigator: Lilyana Amezcua, MD
Phone: 323-442-6021
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Wendy Vargas, MD
Phone: 212-342-4649
?
mi
from
New York, NY
Click here to add this to my saved trials
825 Northeast 13th Street
Oklahoma City, Oklahoma 73104
Principal Investigator: Gabriel Pardo, MD
Phone: 405-271-6241
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Orhun Kantarci, MD
Phone: 507-538-4107
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Robert Naismith, MD
Phone: 314-362-3402
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Antonio, Texas 78258
Principal Investigator: Ann Bass, MD
Phone: 210-490-0016
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
5300 Tallman Ave NW
Seattle, Washington 98122
(206) 782-2700
Principal Investigator: Pavle Repovic, MD
Phone: 206-215-3565
Swedish Medical Center Since 1910, Swedish has been the region's hallmark for excellence in health...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tacoma, Washington 98405
Principal Investigator: Stacy Donlon, MD
Phone: 253-403-7449
?
mi
from
Tacoma, WA
Click here to add this to my saved trials